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ABSTRACT 
The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples 
using deuterated imatinib (D8-IM) as an internal standard. The biological samples were extracted using Strata-
X-C SPE cartridges and separated on C8 column (50 x 3 mm, 3 µm), and methanol: 0.1% formic acid (70:30) 
was delivered at the rate of 0.7 ml/min as a mobile phase.  Imatinib was quantified in samples by monitoring the 
ions m/z 494.3 for imatinib and 502.3 for D8-imatinib on mass spectrometer. The method was linear in the 
concentration range of 1-1500 ng/250 µl in spiked human plasma samples and limit of quantification was 5 
ng/mL. Inter-day and intra-day variations in spiked human plasma spiked with 50, 250 and 500 ng /mL were 
less than 3.16%.  The repeatability and reproducibility and other parameters of the methods were also validated. 
The method was employed for the analysis of the imatinib in human plasma and bone marrow samples. The 
drug levels in bone marrow and plasma samples were correlated to the degree of cytogenetic response. No 
significant difference of imatinib level between blood and bone marrow in IM-treated patients dosed to steady 
state was observed.   
 
Keywords: Bone marrow, Imatinib, Leukaemic, LC- ESI-MS, Human plasma. 
 
  
INTRODUCTION  
 
The selective Abl tyrosine kinase inhibitor, imatinib 
mesylate (IM; Gleevec® or Glivec®) has become the gold 
standard treatment of Chronic Myeloid Leukaemia (CML) 
(Druker et al., 2001; Druker et al., 2001; Saito and 
Morioka, 2010).  Discovered from a rational drug design 
program, IM blocks the activity of BCR-ABL, the 
oncogenic tyrosine kinase created by the Philadelphia 
(Ph) chromosome translocation diagnostic of CML.  
Although clinical studies in the three sequential stages of 
the disease chronic phase (Kantarjian et al., 2002) 
accelerated phase (Talpaz et al., 2002) and terminal blast 
crisis (Kantarjian et al., 2002; Sawyers et al., 2002) 
confirm the substantial activity of the drug in vivo, 
responses are not sustained in advanced phases.  Further, 
the majority of patients in the early chronic phase do not 
achieve the deepest level of response, i.e. molecular 
remission that is polymerase chain reaction (PCR) 
negativity for BCR-ABL (Hughes et al., 2003). Studies 
showed the patients with higher CYP3A responds better 
to imatinib (Green et al., 2003). 
 
Knowing that CML is a clonal disease of stem cell origin, 
it has been postulated that low stem cell turnover in vivo 
may facilitate survival of ‘protected’ quiescent stem cells 
able to maintain and repopulate the disease (Elrick et al., 
2005; Jørgensen et al., 2005).  Physiologically, bone 
marrow is the major compartment for white cell 
production, and this is the compartment in which 
quiescent CML stem cells are presumed to reside.  In the 
face of emerging resistance it would be of interest to 
know the level of IM achieved in patient marrow.  We 
sought to assess whether inadequate patient response was 
in part related to failure to achieve a sufficiently high IM 
level in bone marrow as compared to peripheral blood.  
 
Several methods have been reported for the analysis 
Imatinib using  LC-ESI-MS (Parise et al., 2003; Bakhtiar 
et al., 2002; Guens et al., 2006; Klawitter et al., 2009) 
and HPLC with UV detection and (Rosasco et al., 2005; 
Chahbouni et al., 2009; Roth et al., 2010) methods for the 
analysis of imatinib in plasma or pharmaceutical 
preparations. These methods are commonly based on the 
liquid extraction followed tandem mass spectrometry 
(Hsieh et al., 2009; Ma et al., 2009; De Francia et al., 
2009). The aim of the present study was to develop a 
validated method for the analysis of the IM in plasma and 
bone marrow samples using ESI Ion Trap mass 
spectrometry using solid phase extraction and to evaluate 
the drug levels in plasma and bone marrow samples of the 
CML patients.  *Corresponding author: e-mail: zafar_iqbal@upesh.edu.pk 
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MATERIALS AND METHODS 
 
Reagents and solutions 
Methanol, acetonitrile, Water (HPLC), formic acid (98% 
v/v) and ammonia solution (35% v/v, analytical reagent 
grade) were obtained from BDH Laboratory Supplies 
(Poole, UK).  IM and the internal standard D8-IM were 
kind gifts from Novartis Pharma, Basle, Switzerland.  
Stock IM and internal standard D8-IM solutions at 
1mg/mL were prepared in methanol: 1.0 % w/v formic 
acid (50:50) and stored at +4ºC until analysis.   
 
Clinical samples 
Peripheral blood was collected into glass tube containing 
ethylene diamine tetra-acetic acid (EDTA) after obtaining 
the informed consent from CML patients or healthy 
volunteers according to the Declaration of Helsinki.  Bone 
marrow aspirate, excess to clinical diagnostic 
requirements, was also harvested from the CML patients.  
CML marrow was sampled at 3 or 4 months follow-up 
post-initiation of IM. The plasma supernatant was 
separated by centrifugation of whole blood at 1200 rpm 
for 10 minutes and stored frozen at -20°C until required.  
Glasgow Royal Infirmary Local Research Ethics 
Committee approved the use of human tissue in this 
study. 
 
Solid phase extraction (SPE) method for plasma and 
bone marrow samples 
Frozen peripheral blood plasma or bone marrow samples 
were thawed at room temperature; 0.25 mL was 
transferred to a 1 mL plastic vial and spiked with imatinib 
(250 ng/mL) and appropriate volume of internal standard 
equivalent 10 ng D8-IM and vortex for 30 second. Then 
0.25 ml 0.1M phosphate buffer pH 3.0 was added and 
vortex for further 30 seconds then transferred to a Strata-
X-C column (Phenomenex, Macclesfield, UK) previously 
washed with 1ml of phosphate buffer.  The column was 
washed with 1 mL water, 1 mL methanol, and then twice 
eluted with 1 Ml of ammonium hydroxide (2M) in 
methanol.  The eluent was collected, evaporated under a 
stream of nitrogen and dissolved in formic acid (0.1% 
w/v) and injected into LC-ESI-MS. 
 
Extraction of Samples with Methanol or Acetonitrile 
Plasma (0.25 mL) was spiked with imatinib (250 ng/mL), 
mixed with methanol (1.5 mL) or acetonitrile (1.5 mL) 
and vortexed for 30 seconds then centrifuged at 3600 g 
for 10 min. Then supernatant was collected and 
evaporated under the stream of nitrogen. The residues 
were re-dissolved into formic acid (0.1%). 
 
High pressure liquid chromatography mass 
spectrometry (LC-ESI-MS) for analysis of IM in 
biological fluids  
IM analysis of plasma or bone marrow samples was 
performed using a Spectra Systems HPLC equipped with 
a P2000 pump, AS1000 autosampler with 20 µl fixed 
injection loop and UV2000 detector (ThermoSeparations, 
Hemel Hempstead, Herts, UK). Chromatographic 
separation was conducted at ambient temperature using an 
ACE® 3 µm C8 column (50 x 3 mm internal diameter; 
HiChrom, Reading, UK).  Mobile phase (methanol:formic 
acid 0.1% w/v) in the ratio of 70:30 was delivered in 
isocratic mode at a flow rate of 0.7 mL/min over 10 
minutes. Samples (20 µl) were injected into LC-ESI-MS 
(LCQ Finnigan Automass LC-ESI-MS system) via the 
autosampler without splitting at a flow rate of 0.7 
mL/min.  The interface was operated in positive ion 
electrospray mode at 4.5 kV.  The capillary temperature 
was adjusted to 270°C.  The MS data were acquired under 
selected ion monitoring mode by monitoring for the IM 
ion at m/z 494.3 and at 502.3 for D8-IM. The mass 
spectrums of the IM and D8-IM are shown in Fig 1. 
 
Linearity 
Linearity of the method was studied over the 
concentration range of 1-1500 ng/250 µl in spiked human 
plasma in triplicate by employing the standard calibration 
curves at least 8 points (non-zero standards). However, 
the spiked plasma samples with only internal standard and 
blank plasma sample (non-spiked) was also analysed with 
each batch just to confirm the absence of interferences. 
The method exhibits the linear response in the above 
range with correlation coefficient of 0.998 – 0.9991 (CV 
0.05%) and the regression equation was, y = -0.019 + 
0.001x. 
 
Intra- and inter-day accuracy and precision 
The intra-day precision and accuracy of the assay was 
measured by analysing the three different concentrations 
of spiked human plasma samples at concentration range 
of 50, 250 and 500 ng/250 µl. The intra-day accuracy of 
the method was ranged from 90.2-96.3% and precision 
was (CV) ranged from 2.7-6.9%. The inter-day accuracy 
and precision was determined over three days by 
analysing three spiked human plasma samples at 
concentration range of  50, 250 and 500 ng/250 µl. The 
precision was expressed as the coefficient of variation (% 
CV). 
 
Recovery 
The recovery was evaluated by comparing the peak areas 
of the extracted spikes human plasma samples with the 
un-extracted pure standard solutions at the three 
concentration level i.e. 50, 250 and 500 ng/ml (n=3 for 
each  concentration).    
 
Specificity 
Specificity of the assay was demonstrated by obtaining 
ion-chromatograms for blank pooled human plasma 
samples and blank human plasma spiked with only the 
internal standard. 
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Freeze–thaw stability 
In freeze–thaw stability studies, samples of imatinib and 
CGP 74588 (at three concentrations) were subjected to 
three freeze–thaw cycles and subsequently analyzed in 
duplicate. Plasma samples were stored at −20 °C for 24 h 
and thawed unassisted at room temperature. This cycle of 
thawing and freezing was repeated two more times 
followed by LC–ESI–MS analysis on the third cycle.  
 
 
Limits of detection and limit of quantification 
Limit of detection and quantification were determined 
from the calibration curve of the plasma spiked with 
imatinib, using the following formula: 
 
 
Mass spectrum of Imatinib 
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Mass spectrum of D8-imatinib 
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Fig. 1:  Mass spectrum of imatinib and D8-imitinab under ESI-Ion Trap Mass Spectrometer. 
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Where δ is the residual standard deviation of the 
regression line and S is the slope of the regression line. 
 
Stability 
The stability of imatinib in human plasma was evaluated 
over 3 days at room temperature and stored at –20°C for 
three weeks at three concentrations in duplicate.  
STATISTICAL ANALYSIS 
 
Statistical analysis of the data in this study was performed 
using manitab-8. 
 
RESULTS 
 
The mass spectrum of imatinib and D8-imitinab, used as 
internal standard, under ESI mode of ionozation gave the 
ion [M+1]+ i.e. m/z 494 and m/z 502, respectively as a 
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Fig. 2: The typical spectrum of the imatinib and D8-imatinib extracted from Human plasma (A) and bone marrow (B) 
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base peak. The figs. 1 and 2 show the typical mass 
spectrum of the imitinab and D8-imitinab.  
 
Extraction  
Extraction was carried out using the latter methodology, 
the poorest result was achieved with acetonitrile and 
methanol  as the extraction solvent with only 68% and 
73%, respectively drug recovery in comparison to 89 % ± 
5% IM recovery by SPE (IM at 250 ng in 0.250 ml, n = 
5).  
 
Recovery 
The recovery of the imatinib was evaluated by comparing 
the quantitative results of the spiked human plasma 
samples with the aqueous standard solution of imatinib in 
three different concentrations i.e. 50, 250 and 500 ng/ml 
(n = 3 per concentration) in both medium. The mean 
recovery was 87.1% ± 5.84, 89.1% ± 4.57 and 90.3% ± 
3.84, respectively.  
 
Linearity 
Linearity of the method was studied for the concentration 
range of 1-1500 ng/250 µl in spiked human plasma in 
triplicate by employing the standard calibration curves at 
least 8 points (non-zero standards). The method 
demonstrated the linear response in the above concen-
tration range with correlation coefficient of between 0.998 
– 0.9991 (% CV = 2.9) and the regression equation was, y 
= - 0.0206 + 0.00145x. The calibration curve is shown in 
fig. 3. 
 
Sensitivity 
The limit of detection measures from the calibration curve 
was 0.30 ng/mL and limit of the quatification of the 
method was 0.7 ng/ mL 
 
Precision and accuracy 
The precision and accuracy (expressed as co-efficient of 
variation, % CV) of the intra- and inter-samples were 
studied at three different concentrations i.e. 50, 250 and 
500 ng.ml-1 and was 3.35, 2.59 and 2.49, respectively.  
 
DISCUSSION 
 
Both imitinab and D8-imitinab ions were used for the 
selected ion monitoring (SIM). This method produced 
high-abundance [M +1]+ ions with minimum 
fragmentation of analyte. The MS and HPLC conditions 
for the analysis of imatinib in plasma and bone marrow 
samples were optimized and validated under different 
instrumental conditions.  The optimization of the present 
LC and ESI conditions gave peaks at about 4.5 min and 
yielded high selectivity and sensitivity without 
interference from any other component of the plasma or 
bone marrow.    
 
 
Fig. 3: Calibration curve of imatinib in spiked plasma samples. 
 
Table: Concentration of IM in matched bone marrow and plasma samples (ng/ml) from treated CML patients at 
haematological remission (3 or 4 months). 
 
IM Concentration (µmolar) Sample n Peripheral blood Bone marrow 
All patients 10 967.1 ± 41.28 1261.96 ± 47.16 
CCR  5 1049.7 ± 123.8 1267.85 ± 70.76 
No CCR 5 878.65 ± 70.76 1256.06 ± 141.53 
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Extraction of the imatinib using different methods showed 
that solid phase extraction produce better results 
compared with the solvent extraction. The plasma 
samples were extracted using STRATA Cartridges (SPE), 
methanol and acetonitrile. Extraction of IM from 
biological samples using an SPE method proved to be 
superior to the solvent extraction based approach of 
existing methods (Druker et al., 2001; Parise et al., 2003; 
Widmer et al., 2004).   
 
The ion-chromatograms for blank pooled human plasma 
samples and blank human plasma spiked with only the 
internal standard was free from any interfering 
endogenous substances.  
 
The results indicate that the method is sensitive enough to 
quantify the imatinib in plasma and particularly in bone 
marrow samples.  
 
The mean intra-assay precision and accuracy was within 
close limits. The statistical analysis showed that the 
difference between inter-day or intra-day sample is not 
significant (p > 0.1). Results were entirely satisfactory 
with intra-day accuracy in the range 89% to 98%, and 
inter-day precision (% CV) ranging from 0.6% to 3.5%. 
This indicates that following extraction of the imatinib 
from the biological samples it is stable when stored at 
4°C.  
 
Studies of Imatinib concentration in blood and bone 
marrow samples 
Based on our group’s research interest in persistent 
quiescent CML stem cells within the bone marrow 
compartment, we postulated that truly successful 
chemotherapeutic disease eradication may only be 
achieved if local drug delivery is optimal.  An 
investigation into the correlation of peripheral blood and 
bone marrow plasma drug levels was therefore planned, 
for which a sensitive, precise and accurate analytical 
methodology had to be developed.   
 
From a cohort of 10 CML patients enrolled in a clinical 
trial studying IM in chronic phase (Novartis studies 0106 
and 0113), matched peripheral blood and bone marrow 
aspirate samples were processed to determine drug levels. 
The average IM level in peripheral blood samples taken at 
3 or 4 months post-initiation of IM therapy (table) was in 
keeping with published human pharmacokinetic data 
dosed to steady state (Peng et al.,  2003).  At this time, all 
patients had achieved a haematological remission (to < 10 
x 106/mL). However, only half had achieved the next 
level of response that is a complete cytogenetic response 
(CCR).  None of the patients were PCR-negative for 
BCR-ABL at this stage.  
On analysis of total data from all patients, there was no 
significant difference in the average drug concentration 
between peripheral blood and bone marrow plasma. This 
suggests that 400 mg IM daily is sufficient to sustain 
equilibrium between peripheral blood and bone marrow 
plasma at a therapeutic level (approximately 2 µM). 
When the levels measured in the cytogenetically. 
responding patients were compared with the non-
responders, there were still no significant differences 
between sub-groups in peripheral blood or bone marrow.  
 
In summary, using a sensitive assay for measurement of 
IM in biological samples, we have found that the IM 
concentration in peripheral blood and bone marrow 
plasma from CML patients dosed to steady state is in 
equilibrium. Despite the relatively limited patient 
numbers studied, these data were nonetheless consistent 
demonstrating good distribution of the drug into this 
previously un-assayed tissue. However, as we believe that 
higher intracellular levels of IM are required to kill stem 
cells than mature leucocytes in vitro, due to over- 
expression of BCR-ABL protein and/or multi-drug 
resistance pumps (Copland et al., 2006; Jordanides et al., 
2006) we now hypothesise that more effective 
intracellular stem cell drug loading may be required 
within the bone marrow compartment.  
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